RALEIGH – BioDelivery Sciences International plans to launch in the first quarter of 2022 in the U.S. and Canada an FDA-approved migraine treatment from Dr. Reddy’s Laboratories. The Raleigh firm said Thursday it had closed on the acquisition of the drug.
It’s called ELYXYB. The oral solution is approved for use in adults.
BDSI paid $6 million up front for the drug rights and will pay another $9 million in August 2022 plus other payments based on sales and the reaching of other regulatory milestones.
“ELYXYB represents an excellent strategic fit for BDSI and a very attractive opportunity to diversify our product portfolio by expanding into the dynamic migraine market, deepening our presence in Neurology, a logical adjacency to our pain franchise,” said Jeff Bailey, CEO of BDSI, when the news was first announced.
BDSI also said it plans to conduct a pediatric study, noting the drug has “the potential to address the significant unmet need in the pediatric patient population.”
“The availability of ELYXYB represents a significant therapeutic development for the acute treatment of migraine,” stated Richard Lipton, MD, Edwin Lowe chair in Neurology at Albert Einstein College of Medicine, Director of the Montefiore Headache Center, and one of the clinical investigators for the ELYXYB studies. “With rapid onset of action delivered in a unique, ready-to-use oral solution, ELYXYB provides a convenient, quick relief treatment option to help patients return to functioning in their everyday lives.”
